Abstract
Background. Post-transplant diabetes mellitus (PTDM) is a common metabolic complication in kidney allograft recipients, significantly contributing to the elevated cardiovascular morbidity after renal transplantation and increased risk of chronic transplant dysfunction. The aim of the present investigation was to evaluate the factors influencing PTDM development. Under particular consideration were the elements, existing before the transplantation, especially the modality of dialysis treatment significance, i.e. haemodialysis (HD) versus peritoneal dialysis (PD). Methods. Three hundred and seventy-seven consecutive outpatients who underwent renal transplantation (RTx) in our institution between January 2003 and December 2005 were analysed. PTDM was diagnosed according to the current American Diabetic Association/World Health Organization criteria. Statistical inference was conducted by means of univariate methods (one factor versus PTDM) and multivariate methods in frames of generalized linear model.
Results. In the study group, 72 patients (23.4%) developed PTDM after RTx (55 HD and 17 PD patients). PTDM incidence at 3, 6 and 12 months was 15.9%, 22.1% and 23.4%, respectively. The mean interval from transplantation to the onset of PTDM was 3.08 ± 2.73 months. In univariate analysis, the factors associated with the elevated risk of PTDM appearance were older recipient age, positive family history of diabetes, hypertensive nephropathy as end-stage renal disease cause, higher body mass index at transplantation, treatment by PD, and the graft from an older donor. In multivariate verification, statistical significance remained: older recipient age (P < 0.001), positive family history of diabetes (P = 0.002), and treatment by PD (P = 0.007).
Conclusions.
Treatment by PD appears to be a possible novel factor, not yet reported, which may increase the risk of PTDM development.
Introduction
Post-transplant diabetes mellitus (PTDM) is a common metabolic complication in kidney allograft recipients appearing in 4-30% of patients [1] [2] [3] [4] .
It is also well known that PTDM contributes significantly to the elevated cardiovascular morbidity after kidney transplantation and increased risk of chronic transplant dysfunction [1, 5, 6] . Pathogenesis of PTDM embraces both impairment of insulin secretion and peripheral resistance [7] .
In most studies, the main focus was paid to factors affecting PTDM occurrence in the post-transplantation period, such as the type of calcineurin inhibitor used (cyclosporine versus tacrolimus), acute rejection rate, cumulative steroid dose, viral infection presence, number of HLA mismatches and quality of the transplanted organ [1, [8] [9] [10] [11] .
However, less attention was devoted to factors deriving from chronic dialysis treatment. Therefore, the aim of the present investigation was to evaluate the factors influencing the occurrence of PTDM, including those existing before transplantation in the dialysis period. Under particular consideration was the modality of dialysis treatment with the purpose of determination, whether being treated by peritoneal dialysis (PD) versus haemodialysis (HD) has significance for PTDM appearance.
Materials and methods
A retrospective cohort of 377 consecutive patients who underwent renal transplantation in our institution between January 2003 and December 2005 were analysed. All grafts were transplanted from deceased donors. Three hundred and fifty patients received a first kidney graft, and 27 received a second transplant. During the first 12 months, 5 patients changed transplant centre, 12 patients lost graft function and 4 patients died.
Finally, the study group encompassed 356 kidney allograft recipients with graft functioning >12 months. Forty-eight recipients (13.5%) were already diabetic during dialysis.
Therefore, the final analysis included 308 patients (all Caucasian) whose clinical characteristics (quantitative and qualitative parameters) are presented in Tables 1 and 2 .
Statistical analysis was performed with Statistica 8.0 software by means of univariate methods (one factor versus PTDM): Pearson's chisquare test of independence (testing dependencies between categorical variables), non-parametric Mann-Whitney U-test (comparing means of qualitative variables in the two groups, when binary variable-PDTMcould be the cause of differences), and simple logistic regression (investigating influence of one qualitative variable on PDTM). Multivariate analysis was conducted in frames of generalized linear model (GLM) with the logit link function (investigating many qualitative and categorical variables to test their independent influence on PTDM). Statistical significance was recognized with P-value <0.05. Results with P-value greater than the significance level but <0.1 are also mentioned. The parameters of quantitative variables are given as mean ± SD.
In the cyclosporine subgroup, the steroid administration was as follows: Day 0-perioperative methylprednisolone 500 mg i. The mean yearly cumulative prednisone dose in cyclosporine-receiving patients was 5590 mg compared with 3000 mg in tacrolimus-treated recipients.
In addition, the tacrolimus-treated patients were significantly younger than those taking cyclosporine (mean age, 42.3 ± 14.4 and 47.8 ± 11.4 years, respectively, P = 0.0029).
During the analysis period (12 months post-transplantation), steroid withdrawal was not attempted by any of the patients.
PTDM was diagnosed according to the current American Diabetic Association (ADA)/World Health Organization (WHO) criteria.
The current ADA criteria for diagnosis of diabetes mellitus are: symptoms of diabetes plus casual plasma glucose concentration ≥200 mg/dL (11.1 mmol/L), fasting plasma glucose ≥126 mg/dL (7.0 mmol/L), or a 2-h post-load glucose ≥200 mg/dL (11.1 mmol/L) during an oral glucose tolerance test [12] . Results are given as mean ± SD. BMI, body mass index; CIT cold ischaemia time. *P < 0.05, statistically significant. 
Results
Some disparities appeared between patients treated by HD and PD. Patients on maintenance PD were younger (P = 0.0554), with higher percentage of females (P = 0.0545) and shorter dialysis period (P = 0.0385). PD patients exhibited lesser weight gain during 12 months of post-transplantation follow-up (P = 0.0285) and received more frequently tacrolimus (P = 0.0866) and mycophenolate mofetil (P = 0.0059) than cyclosporine and azathioprine. The average cumulative annual prednisone dose in PD group was 4150 mg versus 4570 mg in HD group. There was also difference in maintenance steroid dose between cyclosporine-and tacrolimus-treated recipients (smaller in tacrolimus group).
In the study group, 72 patients (23.4%) developed PTDM after RTx (55 HD and 17 PD patients). PTDM incidence at 3, 6 and 12 months was 15.9%, 22.1% and 23.4%, respectively. The mean interval from transplantation to the onset of PTDM was 3.08 ± 2.73 months.
The comparison of the recipients with and without PTDM is depicted in Tables 3-5 .
The following factors not connected with transplantation procedure and immunosuppressive regimen used, already existing prior to transplantation, exerted significant impact on PTDM appearance: older recipient age (P < 0.001, OR = 1.050 per 1 year), positive family history of diabetes (P = 0.0046, OR = 2.366), hypertensive nephropathy versus glomerulonephritis, interstitial nephritis, polycystic kidney disease and others as the end-stage renal disease (ESRD) cause (P = 0.0048, OR = 2.452), higher body mass index (BMI) at transplantation day (P = 0.045, OR = 1.066 per 1 kg/m 2 ), and treatment by PD (P = 0.0319, OR = 2.044 with 95% confidence interval of 1.054-3.963).
From the elements operating after transplantation exclusively, older donor age was significantly associated with PTDM (P = 0.032, OR = 1.023 per 1 year). The other considered factors, particularly the type of calcineurin inhibitor used, duration of cold ischaemia time, number of HLA mismatches, cumulative methylprednisolone i.v. dose for acute rejection treatment, gender of donor and recipient, presence of hepatitis C virus (HCV) infection before RTx, cytomegalovirus (CMV) and herpes infections after RTx, and number of RTx (data not inserted), did not predict PTDM development.
In GLM analysis of covariance, the occurrence of PTDM was significantly associated with the age of recipient (P < 0.001, OR = 1.051 per 1 year), family history of diabetes (P = 0.002, OR = 2.665), and PD treatment (P = 0.007, OR = 2.782) ( Table 6 ). The lack of significant influence of other variables on PTDM risk could be the result of the relatively small number of patients for multivariate model. Referring to no discerned differences between the kinds of calcineurin inhibitor used, it should be underlined that the tacrolimus-treated patients were significantly younger than those taking cyclosporine.
Influence of PD on risk of PTDM is even higher in multivariate model because PD patients are younger than HD patients. The difference in risk of PTDM development between PD-and HD-treated patients is depicted in Figure 1 and with respect to the age factor in Figure 2 . Considering the age of recipients, the probability of PTDM appearance was below the age 50 years in PD patients, similar to the rate of occurrence in HD group older than 50 years.
Discussion
In the cohort of kidney transplant recipients under this study, the appearance of PTDM was almost exclusively affected by patient pre-transplant clinical characteristics. The factors significantly augmenting PTDM occurrence were older recipient age (P ≤ 0.001), hypertensive nephropathy as the ESRD cause (P ≤ 0.01), higher BMI at transplantation day (P ≤ 0.05), and PD as the method of renal replacement therapy (P ≤ 0.05 versus HD). The only factor associated with transplant procedure significantly contributing to PTDM development was older donor age (P ≤ 0.05). The multivariate analysis revealed that the independent significant predictors of PTDM development were recipient age, positive family history of diabetes, and PD treatment. The novel finding, not reported in previous literature, is the observation of significantly higher rate of PTDM in the PD-treated patients compared with the number in HD group. The proportion of PD patients with PTDM was 35.4% with 95% confidence interval of 21.3-49.5% versus the proportion of HD patients equal to 21.2% with 95% confidence interval of 15.8-26.6%.
It is of particular note that this association was disclosed in multivariate analysis, albeit PD patients were younger (on the borderline of statistical significance, P = 0.055) and exhibited significantly (P = 0.03) lower weight gain post-transplantation (Table 1) . Furthermore, the periods of dialysis treatment were significantly shorter in PD group (P = 0.04). The possible confounding effect of more frequent tacrolimus use in the PD group (on the borderline of significance P = 0.087) can be excluded based on the fact that there was no relationship between calcineurin inhibitor type and diabetes occurrence in the study group, probably due to extensively smaller accompanying steroid dose in the patients treated with tacrolimus (mean yearly cumulative steroid dose in the tacrolimus group was 3000 mg versus 5590 mg in the cyclosporine patients). In addition, the tacrolimus-treated patients were significantly younger than those taking cyclosporine.
Therefore, our data suggest that the glucose load associated with PD therapy may increase the risk of PTDM development. Recently, Bergrem et al. reported that pretransplant impaired glucose tolerance, revealed by a standard oral glucose tolerance test, was predictive for hyperglycaemia appearance 10 weeks post-transplant. However, they did not consider in the investigation the effect of dialysis modality. The major factor underlying PTDM occurrence in their study population was the recipient age which was previously reported [13] . The mention of PD treatment appears in the latest paper published by Hornum et al. after this manuscript submission [14] . In a smaller group of 57 kidney transplant recipients from live donors, they did not observe the impact of positive family history of diabetes and PD as treatment modality on PTDM occurrence.
Noteworthy, according to our data, the risk of PTDM in PD patients below age 50 years was similar to the risk in HD patients above 50 years, with starting point of risk increase at age 40 years.
The remaining elements, i.e. hypertensive nephropathy, higher BMI and older donor age, were strongly correlated with the age of recipients. In fact, it reflects the more frequent occurrence of hypertensive nephropathy and BMI increase in older recipients, and the higher probability to receive allograft from older donor. The lack of difference in PTDM frequency between cyclosporineand tacrolimus-treated patients seems to be caused by higher Results are given as mean ± SD. BMI, body mass index; CIT, cold ischaemia time. *P < 0.05, statistically significant. The increased risk of PTDM in PD-treated kidney recipientsaccompanying prednisone doses in our cyclosporine-based immunosuppressive regimen. In summary, the present study has identified the features of the recipients associated with an elevated risk of PTDM development, such as older age, family history of diabetes, hypertensive nephropathy as ESRD cause, higher BMI at transplantation, treatment by PD, and the graft from an older donor. The recipients carrying these features should undergo detailed pre-transplant glucose metabolism evaluation with oral test for glucose intolerance, and be considered for calcineurin inhibitors or steroid-minimization protocols. It is of note that 49 cases of PTDM from the total number of 72 cases during 1 year were developed during the first 3 months post-transplantation.
Conclusions
In evaluating the risk of PTDM occurrence, more attention should be paid to the stratification of the predisposing abnormalities present during the dialysis period. Treatment by PD may increase the risk of PTDM development.
